Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22291225 | 0.89 | L3MBTL1 (0.58) | NPC1RAB9ATDP1TNFRSF1AALDH1A1 | |
| SCHEMBL22291222 | 0.82 | NPC1 (0.54) | NPC1RAB9ATDP1TNFRSF1AALDH1A1 | |
| SCHEMBL12335182 | 0.81 | TACR2 (0.60) | NPC1RAB9ATDP1ALDH1A1MAPT | |
| SCHEMBL9097669 | 0.80 | FDPS (0.47) | TDP1ALDH1A1MAPTL3MBTL1LMNA | |
| SCHEMBL22291067 | 0.78 | NPC1 (0.59) | NPC1RAB9ATDP1TNFRSF1AALDH1A1 | |
| SCHEMBL3629871 | 0.78 | NPC1 (0.59) | NPC1RAB9ATDP1TNFRSF1AALDH1A1 | |
| SCHEMBL22291105 | 0.78 | NPC1 (0.50) | NPC1RAB9ATDP1TNFRSF1AALDH1A1 | |
| SCHEMBL7844422 | 0.77 | TUBB1 (0.57) | ALDH1A1MAPTLMNAPDCD1CD274 | |
| SCHEMBL7466433 | 0.77 | FDPS (0.53) | RAB9ATDP1TNFRSF1AALDH1A1MAPT | |
| SCHEMBL8983142 | 0.76 | NPC1 (0.65) | NPC1RAB9ATDP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195450-B2 | Small molecule neutral sphingomyelinase 2 (nSMase2) inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20220119374-A1 | SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (nSMase2) INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2022-04-21 | — | — | US | disclosed |
| EP-3917530-A1 | SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) INHIBITORS | The Johns Hopkins University (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160148-A1 | SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195450-B2 | Small molecule neutral sphingomyelinase 2 (nSMase2) inhibitors | SMPD2, SPTLC2, SGMS2 | NPC1 114/4885RAB9A 1081/4885TDP1 826/4885 |
| US-20220119374-A1 | SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (nSMase2) INHIBITORS | SMPD2, SPTLC2, SGMS2 | NPC1 114/4885RAB9A 1081/4885TDP1 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.